Adjuvant atezolizumab in surgically resected NSCLC patients with PD-L1 expression ≥ 50%: real-world data from the Italian ATLAS registry.

ABSTRACT:

Background

This study describes clinical characteristics, treatment patterns as well as safety outcomes of NSCLC patients harboring PD-L1 ≥ 50% who received adjuvant atezolizumab within the Italian real-world scenario.

Methods

Patients with surgically resected NSCLC harboring EGFR/ALK wild type disease and PD-L1 TPS ≥ 50%, who received at least one cycle of adjuvant atezolizumab were included. Clinical-pathological and molecular data, safety and efficacy outcomes were collected from the Italian ATLAS real-world registry.

Results

A total of 132 patients were included across 45 Italian centers between July 2022 and August 2024. Lobectomy was performed in 81.1% of cases, with 8.3% pathological stage IIA, 40.2% stage IIB, 43.9% stage IIIA, and 7.6% stage IIIB, according t

SUBMITTER: Passiglia F 

PROVIDER: S-EPMC12854775 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature